SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Avidity Biosciences Inc RNAM NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Avidity Biosciences Inc (RNAM) is a Biotechnology company in the Healthcare sector, currently trading at $72.86. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $19M, +29.9%/yr average growth. Net income is $685M (loss), growing at -62.1%/yr. Net profit margin is -3650.4% (negative). Gross margin is 77.9% (-7.1 pp trend).

Balance sheet: total debt is $95M against $1.7B equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 9.2 (strong liquidity). Debt-to-assets is 4.8%. Total assets: $2.0B.

Analyst outlook: 2 / 11 analysts rate RNAM as buy (18%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 53/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

RNAM SharesGrow Score Overview

48/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 53/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RNAM

No analyst coverage available for this stock.

RNAM: +29.9%/yr revenue is, -62.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet RNAM: Debt-to-Equity (D/E) ratio 0.06 (conservative), Current ratio is 9.2 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

RNAM: Gross margin is 77.9% (-7.1 pp trend), $11B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 53/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 11 analysts rate RNAM as buy (18%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

RNAM: Net profit margin is -3650.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range21.51-73.06

Volume1

Avg Volume (30D)2.7M

Market Cap$11.26B

Beta (1Y)0.93

Share Statistics

EPS (TTM)-4.97

Shares Outstanding$137.71M

IPO Date2020-06-12

Employees511

CEOSarah Boyce

Financial Highlights & Ratios

Revenue (TTM)$18.76M

Gross Profit$14.6M

EBITDA$-741.79M

Net Income$-684.63M

Operating Income$-745.94M

Total Cash$1.7B

Total Debt$94.56M

Net Debt$-287.95M

Total Assets$1.96B

Price / Earnings (P/E)-14.7

Price / Sales (P/S)600.12

Analyst Forecast

Rating ConsensusHold

Analysts Covering11

Buy 18% Hold 82% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS05370A1088

Price Chart

RNAM

Avidity Biosciences Inc ↗ · NASDAQ Global Market

Healthcare • Biotechnology

21.51 52WK RANGE 73.06

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message